4-氨基吡啶是治疗KCNA2功能获得性脑病的有前景选择
本研究针对KCNA2脑病,通过体外实验证明钾通道阻滞剂4-氨基吡啶可拮抗KV1.2亚基变异导致的功能获得性缺陷,并在九中心n-of-1试验中观察11例携带此类变异患者,9例获益,6例每日发作患者均无发作,耐受性良好。
要点
- 4-氨基吡啶可拮抗KCNA2功能获得性变异所致KV1.2通道缺陷。
- n-of-1试验中11例患者9例获益,6例每日发作患者均无发作。
- 4-氨基吡啶耐受性良好,剂量可达每日2.6 mg/kg。
核心结论
- 4-氨基吡啶是KCNA2功能获得性脑病的有前景的定制治疗方案。
研究设计与样本
- 体外实验研究KCNA2变异对KV1.2通道功能的影响及4-氨基吡啶的作用。
- 在九个中心开展n-of-1试验,纳入11例携带KCNA2功能获得性变异的患者。
主要发现
- 体外实验中4-氨基吡啶降低电流幅度、逆转稳态激活负向偏移并增加转染神经元放电频率。
- n-of-1试验中11例患者有9例从4-氨基吡啶治疗中获益。
- 6例每日出现失神、肌阵挛或失张力发作的患者均达到无发作(除部分诱发性发作外)。
- 6例全面性强直-阵挛发作患者中2例显著改善、3例无效、1例加重。
- 9例患者步态、共济失调、警觉性、认知或言语改善。
关键数值与推荐
- 4-氨基吡啶耐受性良好,剂量可达每日2.6 mg/kg。
- 建议将4-氨基吡啶作为KCNA2功能获得性脑病的定制治疗选择。
- 提供在线工具辅助医生筛选适合该治疗的功能获得性突变患者。
临床怎么用
- 对携带KCNA2功能获得性变异的脑病患者可考虑试用4-氨基吡啶。
- 使用在线工具辅助筛选适合4-氨基吡啶治疗的功能获得性突变患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Developmental and epileptic encephalopathies are devastating disorders characterized by epilepsy, intellectual disability, and other neuropsychiatric symptoms, for which available treatments are largely ineffective. Following a precision medicine approach, we show for KCNA2-encephalopathy that the K+ channel blocker 4-aminopyridine can antagonize gain-of-function defects caused by variants in the KV1.2 subunit in vitro, by reducing current amplitudes and negative shifts of steady-state activation and increasing the firing rate of transfected neurons. In n-of-1 trials carried out in nine different centers, 9 of 11 patients carrying such variants benefitted from treatment with 4-aminopyridine. All six patients experiencing daily absence, myoclonic, or atonic seizures became seizure-free (except some remaining provoked seizures). Two of six patients experiencing generalized tonic-clonic seizures showed marked improvement, three showed no effect, and one worsening. Nine patients showed improved gait, ataxia, alertness, cognition, or speech. 4-Aminopyridine was well tolerated up to 2.6 mg/kg per day. We suggest 4-aminopyridine as a promising tailored treatment in KCNA2-(gain-of-function)–encephalopathy and provide an online tool assisting physicians to select patients with gain-of-function mutations suited to this treatment.
引用
- Hedrich UBS, Lauxmann S, Wolff M, et al. 4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2-encephalopathy. Sci Transl Med. 2021. PMID: 34516822. doi:10.1126/scitranslmed.aaz4957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。